No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Labcorp Holdings, Inc. delivers specialized diagnostic laboratory services. Its purpose is to empower a diverse group of stakeholders – including medical professionals, hospitals, pharmaceutical companies, scientific researchers, and individual patients – to arrive at well-informed and confident decisions. The organization commenced operations on April 16, 2024, and conducts its central management from its headquarters in Burlington, North Carolina.
www.labcorp.comNo one on the platform currently holds 0JSY.L.
No tracked institution reports a position in 0JSY.L as of their last filing.
No one on the platform has traded 0JSY.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.9% | 8.8% | 9.4% | — | — | — |
| Rev. Growth % | 7.2% | -0.0% | ||||
| Profit Margin % | 6.3% | 8.2% | 8.7% | |||
| Free Cash Flow Margin % | 8.6% | 10.7% | 10.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $14.8B | +5.4% | $18.35 | $18.18–$18.57 | — | 1 |
| 2027 | $15.5B | +4.9% | $19.90 | $19.72–$20.14 | — | 1 |
| 2028 | $16.2B | +4.9% | $21.67 | $21.48–$21.93 | — | 1 |
| 2029 | $17.3B | +6.3% | $24.00 | $23.78–$24.28 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $4.78 | $4.99 | +4.4% |
| 2026-04-30 | $4.11 | $4.25 | +3.4% |
| 2026-02-17 | $3.95 | $4.07 | +3.0% |
| 2025-10-28 | $4.13 | $4.18 | +1.2% |
| 2025-07-24 | $4.17 | $4.35 | +4.3% |
| 2025-04-29 | $3.74 | $3.84 | +2.7% |
| 2025-02-06 | $3.39 | $3.45 | +1.8% |
| 2024-10-24 | $3.47 |
| $3.50 |
| +0.9% |
| $34.3B |
| — |
| 0J9P.LIncyte Corporation | $121.28 | -0.97% | $24.0B | — |
| 0KSX.LQuest Diagnostics Incorporated | $247.24 | +4.94% | $27.3B | — |
Source: Financial Modeling Prep · peers by sector/industry